0000899243-21-024574.txt : 20210617
0000899243-21-024574.hdr.sgml : 20210617
20210617211547
ACCESSION NUMBER: 0000899243-21-024574
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210617
FILED AS OF DATE: 20210617
DATE AS OF CHANGE: 20210617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gengos Andrew
CENTRAL INDEX KEY: 0001563623
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40499
FILM NUMBER: 211026884
MAIL ADDRESS:
STREET 1: 21900 BURBANK BOULEVARD
STREET 2: 3RD FLOOR
CITY: WOODLAND HILLS
STATE: CA
ZIP: 91367
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662244
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 455429901
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING A, SUITE 510
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 857-285-4140
MAIL ADDRESS:
STREET 1: 128 SPRING STREET
STREET 2: BUILDING A, SUITE 510
CITY: LEXINGTON
STATE: MA
ZIP: 02421
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-06-17
0
0001662244
Cyteir Therapeutics, Inc.
CYT
0001563623
Gengos Andrew
128 SPRING ST, BUILDING A, SUITE 510
LEXINGTON
MA
02421
0
1
0
0
Chief Business Officer
Common Stock
73534
D
Stock Option (Right to Buy)
1.19
2030-03-23
Common Stock
55151
D
Stock Option (Right to Buy)
1.19
2030-03-23
Common Stock
147070
D
Stock Option (Right to Buy)
7.09
2031-02-21
Common Stock
102927
D
Includes 4,595 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest.
The option vests as to 75% of the underlying shares of common stock on February 24, 2023, and as to the remaining shares underlying the award in 12 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
The option vests as to 25% of the underlying shares of common stock on February 24, 2021, and as to the remaining shares underlying the award in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date.
By: /s/ Andrew Gengos
2021-06-17